RxDoctor Payments Data

Joseph Chung, MD

Family Medicine · Arlington, TXNPI 1932187416

Payments from drug & device makers

$618in general payments, 2019–2025

Across 16 payments — averaging $38.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$314
  • AstraZeneca$93
  • Myriad Genetic Laboratories, Inc.$78
  • Exact Sciences$42
  • Lilly USA, LLC$33
  • Biotronik NRO, Inc.$28
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$618100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$618 in reported general payments places this provider in the 50th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$24,143
Medicare patients
89
Services billed
409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin42$59,577
OzempicSemaglutide22$21,208
TrulicityDulaglutide20$18,476
MounjaroTirzepatide17$17,455
XareltoRivaroxaban14$15,195
Albuterol Sulfate HfaAlbuterol Sulfate33$1,070
Omeprazole57$987
Atorvastatin Calcium143$918
Rosuvastatin Calcium93$827
Gabapentin37$733
Metoprolol Succinate46$706
Levothyroxine Sodium82$672
Amlodipine Besylate126$644
Venlafaxine Hcl ErVenlafaxine Hcl26$621
Losartan Potassium72$618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$19$59,57742 claims
Lilly USA, LLCTrulicity, Mounjaro$33$35,93137 claims
Novo NordiskOzempic$314$21,20822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →